Amlodipine/rosuvastatin/telmisartan - Jeil Pharmaceutical
Alternative Names: JLP-1401; Telmiduo PlusLatest Information Update: 15 Feb 2022
At a glance
- Originator Jeil Pharmaceutical
- Class Antihyperlipidaemics; Antihypertensives; Benzimidazoles; Benzoates; Dihydropyridines; Fluorobenzenes; Ischaemic heart disorder therapies; Pyrimidines; Small molecules; Sulfonamides
- Mechanism of Action ACE inhibitors; Angiotensin type 2 receptor antagonists; Calcium channel antagonists; Cytochrome P 450 enzyme system inhibitors; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Dyslipidaemias; Hypertension
Most Recent Events
- 12 Sep 2019 Jeil Pharmaceutical completes a phase I trial for Hypertension in volunteers in South Korea (NCT03707899)
- 15 Nov 2018 Jeil Pharmaceutical initiates a phase I trial for hypertension in volunteers in South Korea (NCT03707899)
- 23 Oct 2018 Jeil Pharmaceutical plans a phase I trial in healthy volunteers (PO) (NCT03707899)